NetworkNewsBreaks – Agenus, Inc. (NASDAQ: AGEN) Launches New AgenTus Therapeutics Subsidiary, Names CEO
Shares of Agenus (NASDAQ: AGEN) are up 3.7% this morning after the company launched a new subsidiary company, AgenTus Therapeutics, Inc., for its cell therapy business. AgenTus will focus on the discovery, development, and commercialization of breakthrough immuno-oncology (I-O) "living drugs" to advance potential cures for cancer patients. Bruno Lucidi has been appointed as CEO of the AgenTus subsidiary. "AgenTus will operate with remarkable science, innovation, and access to Agenus capabilities and expertise, all giving the subsidiary competitive advantage through the delivery of innovative living drugs to cancer patients looking for cures," Agenus chairman and CEO Garo Armen, Ph.D. stated…







